What is MK-8527 studying for healthy adults?

MK-8527 is being studied to understand how it behaves in the body when taken alone, with food, or combined with other medicines. Researchers aim to learn about its safety and how well people tolerate it. This study is sponsored by Merck Sharp & Dohme LLC.

Who may be eligible for this healthy volunteer clinical trial?

Adults aged 18 to 55 who are in good health and have a BMI between 18 and 32 may be eligible. People with a history of cancer, significant medical conditions, or certain surgeries may not qualify. Please review eligibility criteria for more details.

Is there any cost to participate in this healthy volunteer clinical trial?

Study-related care, including the study drug and all trial visits, is provided at no cost. However, personal travel expenses may vary and are not guaranteed to be covered.

Actively Recruiting

Phase 1

Age: 18Years - 55Years

All Genders

Healthy Volunteers

ID07661108

Study of How Food and Other Medicines Affect MK-8527 in Healthy Adults Ages 18 to 55

Led by Merck Sharp & Dohme LLC · Updated on 2026-07-02

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are studying a medicine called MK-8527 to understand how it behaves in the bodies of healthy adults aged 18 to 55. The study aims to learn how MK-8527 interacts when taken with food or combined with other medicines like probenecid and itraconazole. The goal is also to assess the safety of MK-8527 and whether participants can tolerate it without needing to stop due to health issues. Participants will receive single doses of MK-8527 under different conditions with food and without food, alone and combined with probenecid, and alone and combined with itraconazole. This crossover study allows each participant to experience all these dosing scenarios to compare how the medicine behaves in each case. During the study, participants will be monitored through blood and urine tests at specified times up to 336 hours after dosing to measure MK-8527 levels and its clearance. Researchers will also track any side effects or reasons for stopping treatment over approximately 43 days. The study is conducted by Merck Sharp & Dohme LLC and is expected to complete in October 2026.

CONDITIONS

Brief Title

A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)

Who Can Participate

Age: 18Years - 55Years

All Genders

Healthy Volunteers

Eligibility Criteria

You may qualify if you...

Be in good health
Have a body mass index (BMI) between 18 and 32 kg/m², inclusive
Be between 18 and 55 years old

You will not qualify if you...

Have an estimated glomerular filtration rate (eGFR) less than or equal to 90 mL/min/1.73 m²
Have a history of serious endocrine, gastrointestinal, cardiovascular, blood, liver, immune, kidney, lung, genitourinary, or major neurological conditions including stroke or chronic seizures
Have had stomach or intestinal surgery that could affect drug absorption or excretion (simple appendectomy and hernia repair allowed)
Have a history of cancer (malignancy)
Are taking any medication containing emtricitabine (FTC) or lamivudine (3TC)

Research Team

Toll Free Number

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here